- Welcome to Specialised Therapeutics
-
SE Asia
+65 3158 9940
-
1300 798 820
-
New Zealand
+64 9801 0299
May 2017 - ST acquires rights to anti-cancer compound ZEPZELCA® (lurbinectedin)
ST signs a second major licensing deal with European pharmaceutical company PharmaMar.